Evidence map›Paper›PMID 34664791›Full record

Observational studyPharmacology research & perspectives2021

Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.

Tetsuichiro Isono, Daiki Hira, Aya Morikochi, Tadateru Fukami, Satoshi Ueshima, Kazuhiko Nozaki, Tomohiro Terada, Shin-Ya Morita

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tetsuichiro IsonoDepartment of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan.ORCID 0000-0001-5771-3819
Daiki HiraDepartment of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan.ORCID 0000-0001-8344-2469
Aya MorikochiDepartment of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan.
Tadateru FukamiDepartment of Neurosurgery, Shiga University of Medical Science, Otsu, Shiga, Japan.
Satoshi UeshimaCollege of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan.
Kazuhiko NozakiDepartment of Neurosurgery, Shiga University of Medical Science, Otsu, Shiga, Japan.
Tomohiro TeradaDepartment of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan.
Shin-Ya MoritaDepartment of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Shiga, Japan.ORCID 0000-0003-4079-707X
Shiga University of Medical Science Hospital · JPRitsumeikan University · JPShiga University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose methotrexate (HD-MTX)-based chemotherapy is the first-line treatment for primary central nervous system lymphoma (PCNSL), but is associated with severe adverse effects, including myelosuppression and renal impairment. MTX is primarily excreted by the kidneys. Renal function calculated using serum creatinine (Scr) derived from muscle may be overestimated in elderly PCNSL patients. Therefore, we aimed to construct a population pharmacokinetic model in PCNSL patients and explore the factors associated with MTX clearance. Sixteen PCNSL patients (median age, 66 years) treated with HD-MTX were included, and serum MTX concentrations were measured at 193 points in 49 courses. A population pharmacokinetic analysis was performed using NONMEM. A Monte Carlo simulation was conducted, in which serum MTX concentrations were stratified into three groups of creatine clearance (Ccr) (50, 75, and 100 ml/min) with three groups of the urine volume to hydration volume (UV/HV) ratio (<1, 1-2, and >2). The final model was constructed as follows: MTX clearance = 4.90·(Ccr/94.5)

Indexed as

AgedAged, 80 and overAntimetabolites, AntineoplasticCentral Nervous System NeoplasmsCreatinineDose-Response Relationship, DrugFemaleHumansKidney Function TestsLymphomaMaleMethotrexateMiddle AgedMonte Carlo MethodRetrospective StudiesAntimetabolites, AntineoplasticCreatinineMethotrexatecreatinine clearancehigh-dose methotrexatehydration volumepopulation pharmacokineticsprimary central nervous system lymphomaurine volume

Identifiers

PMID34664791
PMCPMC8525095
OpenAlexW3206167803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.